Teva Pharmaceutical Industries Ltd. announced that the U.S. Court of Appeals for the Federal Circuit affirmed the May 2002 decision of the U.S. District Court for the Eastern District of Virginia in Teva's successful challenge of GlaxoSmithKline's patent position relating to Augmentin.

Israel Makov, president and CEO of Teva commented: "Teva is very pleased with this decision, which will allow us to continue to provide a more affordable generic version of Augmentin to consumers in the United States. We have always believed that we had a strong case that would be upheld by the Court of Appeals, but the decision itself obviously now settles the matter."